NDC 68982-820-86 - Panzyga
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 68982-820
- Requested NDC
- 68982-820-86
- Package NDCs from labels
- 68982-820-81, 68982-820-01, 68982-820-82, 68982-820-02, 68982-820-83, 68982-820-03, 68982-820-84, 68982-820-04, 68982-820-85, 68982-820-05, 68982-820-86, 68982-820-06
- Manufacturer
- Octapharma USA Inc
- Effective date
- 2021-02-15
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Panzyga - Octapharma USA Inc | Octapharma USA Inc | 2021-02-15 | PLASMA DERIVATIVE |
FDA-Initiated Inactive NDC Indexing#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68982-820-01 | Panzyga | 1 in 1 CARTON | SOLUTION | 1 | 11 | |
| 68982-820-02 | Panzyga | 1 in 1 CARTON | SOLUTION | 1 | 11 | |
| 68982-820-03 | Panzyga | 1 in 1 CARTON | SOLUTION | 1 | 11 | |
| 68982-820-04 | Panzyga | 1 in 1 CARTON | SOLUTION | 1 | 11 | |
| 68982-820-05 | Panzyga | 1 in 1 CARTON | SOLUTION | 1 | 11 | |
| 68982-820-06 | Panzyga | 1 in 1 CARTON | SOLUTION | 1 | 11 | |
| 68982-820-81 | Panzyga | 10 mL in 1 BOTTLE, GLASS | SOLUTION | 10 | 11 | |
| 68982-820-82 | Panzyga | 25 mL in 1 BOTTLE, GLASS | SOLUTION | 25 | 11 | |
| 68982-820-83 | Panzyga | 50 mL in 1 BOTTLE, GLASS | SOLUTION | 50 | 11 | |
| 68982-820-84 | Panzyga | 100 mL in 1 BOTTLE, GLASS | SOLUTION | 100 | 11 | |
| 68982-820-85 | Panzyga | 200 mL in 1 BOTTLE, GLASS | SOLUTION | 200 | 11 | |
| 68982-820-86 | Panzyga | 300 mL in 1 BOTTLE, GLASS | SOLUTION | 300 | 11 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ASCENIV | HUMAN IMMUNOGLOBULIN G | ADMA Biologics, Inc. | d74f4360-3b51-496c-96fb-84c3976958d2 | 2026-09-29 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| BIVIGAM | IMMUNE GLOBULIN INTRAVENOUS (HUMAN) 10% | ADMA Biologics, Inc. | a2244aa0-a6d0-11df-b385-0002a5d5c51b | 2026-09-29 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| YIMMUGO | IMMUNE GLOBULIN INTRAVENOUS, HUMAN - DIRA | Kedrion Biopharma Inc | 50fc5ffc-49aa-51f2-e063-6294a90a59cf | 2026-07-15 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Privigen | HUMAN IMMUNOGLOBULIN G | CSL Behring AG | 7e5649da-75be-4a42-8eeb-4aeba562c401 | 2026-05-04 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| YIMMUGO | IMMUNE GLOBULIN INTRAVENOUS, HUMAN - DIRA | Biotest AG | 77aaac18-f2af-46c4-8f65-b15be1cec3c2 | 2026-03-01 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| QIVIGY kthm | HUMAN IMMUNOGLOBULIN G | Kedrion S.p.A. | 6f1933e0-240f-48f4-b246-8a30e63a4160 | 2026-02-02 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| GAMMAGARD Liquid | IMMUNE GLOBULIN INFUSION (HUMAN) | Takeda Pharmaceuticals America, Inc. | 9d42adca-0dd7-4df7-864d-5a7feee52130 | 2025-12-10 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| CUVITRU | IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN) | Takeda Pharmaceuticals America, Inc. | 9aad7ec9-6097-4805-8f1b-898bec35f218 | 2025-11-25 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| GAMMAGARD Liquid ERC | IMMUNE GLOBULIN INFUSION (HUMAN) | Takeda Pharmaceuticals America, Inc. | 1341fd31-0754-47f0-a4d6-7255056b6541 | 2025-10-30 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Gammaplex | HUMAN IMMUNOGLOBULIN G | Bio Products Laboratory Ltd | 2098af41-aec7-4af7-98bb-54f8ab55f30e | 2025-10-23 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Alyglo | HUMAN IMMUNOGLOBULIN G | GC Biopharma Corp. | fb97b3ec-29ee-4df1-aa99-c23e57a21228 | 2025-06-05 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Panzyga | IMMUNE GLOBULIN INTRAVENOUS (HUMAN) | Octapharma USA Inc | 9306c5f7-ddf9-5190-d0c1-31ba9ca2d0e0 | 2025-05-08 | Boxed warning, Warnings, Adverse reactions | BLA125587 2102455 2102435 2102472 2102463 2102469 2102470 2102464 2102456 2102460 2102459 2102471 2102440 66Y330CJHS |
| Panzyga | IMMUNE GLOBULIN INTRAVENOUS (HUMAN) | Pfizer Laboratories Div Pfizer Inc | e2cc5ddf-119e-ade3-79c2-c712cfbee099 | 2025-05-08 | Boxed warning, Warnings, Adverse reactions | BLA125587 2102455 2102435 2102472 2102463 2102469 2102470 2102464 2102456 2102460 2102459 2102471 2102440 66Y330CJHS |
| Cutaquig | IMMUNOGLOBULIN G | Pfizer Laboratories Div Pfizer Inc | f199187a-de4e-2047-0aee-b6d93390b3d2 | 2025-03-24 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Octagam Immune Globulin (Human) | IMMUNE GLOBULIN | Pfizer Laboratories Div Pfizer Inc | fb07257b-e5e2-64c8-666c-65009f0aa604 | 2024-01-29 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Octagam Immune Globulin (Human) | IMMUNE GLOBULIN | Pfizer Laboratories Div Pfizer Inc | eb4c342b-122c-0072-1428-1747882e6c00 | 2024-01-26 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Hizentra | HUMAN IMMUNOGLOBULIN G | CSL Behring AG | 7b58f5ff-0316-49a3-b585-1f6003ddb953 | 2023-04-20 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Octagam Immune Globulin (Human) | IMMUNE GLOBULIN | Octapharma USA Inc | de00abeb-d635-eddc-b603-10708ecef5aa | 2022-04-19 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Octagam Immune Globulin (Human) | IMMUNE GLOBULIN | Octapharma USA Inc | a36a12dc-16be-b135-466f-393954f428a7 | 2022-04-08 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| Cutaquig | IMMUNOGLOBULIN G | Octapharma USA Inc | f3de095f-791a-85dc-7a14-ec7790cb13aa | 2021-11-30 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.